Clinical trial · Interventional
HistScanning- Based PDR Brachytherapy in Prostate Cancer HistoScanning- Based Interstitial PDR Brachytherapy
HistoScanning- Based Dose-painting Image-guided Interstitial PDR-brachytherapy in Prostate Cancer - a Phase II Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase II trial looking at the feasibility of HistoScanning- based dose-painting image- guided interstitial brachytherapy in non- metastatic prostate cancer Endpoints: Primary endpoint Evaluation of the feasibility of HistoScanning- based dose-painting image- guided interstitial brachytherapy Secondary endpoints 1. Evaluating tumor response using HistoScanning 2. Evaluating locoregional recurrence rates by measuring PSA 3. Analysis of the correlation between tumor response as determined by HistoScanning and PSA response 4. Evaluating the safety dose-painting image- guided interstitial brachytherapy by recording serious adverse events
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| brachytherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Brachytherapy
- interventionNames
- Radiation: brachytherapy
Primary outcomes (1)
- measure
- Evaluation of the feasibilty of histoscanning- based dose-painting image- guided interstitial brachytherapy
- timeFrame
- 5 years
Secondary outcomes (1)
- measure
- assessing tumor response and side effects
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven prostate cancer * All cT1-3 carcinomas independent of grading and PSA value * Prostate volume\< 70cc * No distant metastases * Karnofsky \> 60 * Written informed consent from the patient regarding study participation Exclusion criteria: * All patients who do not meet the inclusion criteria * T4 carcinomas * Proven metastases N+ and/or M1 * Epidural or general anaesthesia not possible * Pathological clotting parameters
References
Publications (1)
- DERIVEDStrnad V, Lotter M, Kreppner S, Fietkau R. Brachytherapy focal dose escalation using ultrasound based tissue characterization by patients with non-metastatic prostate cancer: Five-year results from single-center phase 2 trial. Brachytherapy. 2022 Jul-Aug;21(4):415-423. doi: 10.1016/j.brachy.2022.02.003. Epub 2022 Apr 6. PMID 35396138